|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AnorMED Inc., of Vancouver, British Columbia, said Fosrenol (lanthanum carbonate) did not cause adverse effects over 12 months of therapy in a Phase III multicenter study of 98 patients who were starting renal dialysis for the first time. In the lanthanum patients, there was no evolution toward low bone turnover states. The data were presented at the international symposium "Advances in Renal Osteodystrophy" in Oviedo, Spain.
Biogen Inc., of Cambridge, Mass., reported revised financial guidance for the second quarter and full year 2002, due to inventory adjustments by U.S. Avonex wholesalers in April and May. Biogen said it expects second-quarter U.S. Avonex ...